Specimen research dossier · literature, mechanisms, and image-reference intake
Human effects & evidence register — clinical research vs. firsthand accounts
Evidence warning: No verified controlled human clinical trial administering identified Gymnopilus junonius was established in the sources reviewed (17 October 2026). Historical G. spectabilis reports involve taxonomic uncertainty. Published trials of pharmaceutical psilocybin do not establish this particular collection's chemistry, effects, potency, or a safe ingestion amount.
DIRECT SPECIES CHEMISTRYCELL / LABOTHER COMPOUND — HUMAN RCTONLINE ANECDOTE
Reported experiences and adverse effects
| Effect | What has been documented | Evidence classification |
| Changes in perception and visual imagery | Published case history describes an earlier report of hallucinogenic G. spectabilis; self-described users also describe mild visual effects. Chemical confirmation is not established for the internet accounts. | Historical report + anecdote (not a controlled trial) |
| Laughter, uplifted or altered mood | Appears in the “Laughing Gym” common name and self-described accounts; no controlled human outcome measure for this species. | Online anecdote; causation unknown |
| Relaxation and unusual body sensations | Reported online by individuals attributing experiences to the Gymnopilus complex. Co-ingestions and species uncertainty limit interpretation. | Online anecdote |
| Little or no noticeable effect | Some self-described users report inconsistent batches, including no effect. May reflect species, compounds, preparation, or reporting biases. | Online anecdote |
| Headache, nausea, dizziness, fatigue | Documented in controlled human trials of purified psilocybin. These are not measured adverse-event rates for Gymnopilus mushrooms. | Human RCT — purified psilocybin only |
| Acute anxiety, psychological distress | Adverse psychological reactions are relevant to human psilocybin research. Individual risks cannot be extrapolated to a particular untested wild mushroom. | Human clinical literature — purified psilocybin only |
| Antidepressant signal under supervised conditions | A 2022 phase-2 depression trial reported a larger improvement in depressive symptom scores at three weeks in one purified-psilocybin trial arm. This does not establish antidepressant efficacy for any Gymnopilus species. | Human RCT — purified psilocybin only |
Primary laboratory and chemistry findings
Hatfield & Valdes (1978) — historically identified Gymnopilus collections
Analytical detection of psilocybin was reported in specimens then identified as G. spectabilis and certain other Gymnopilus species. This did not establish consistent presence in all geographic collections, modern taxonomic identity, or a standardized human exposure profile.
PubMed · PMID 565861
Kusano and colleagues (1986) — contrasting Japanese collection
The chemical-constituent study reported no detected psilocybin or related compounds in its examined G. spectabilis material, documenting an important geographic/collection and identification caveat.
Chemical and Pharmaceutical Bulletin · DOI 10.1248/cpb.34.3465
Gymnopilins — nicotinic receptor experiments (2014)
Cellular studies examined gymnopilin-related inhibition of nicotinic acetylcholine receptor responses. These are in-vitro pharmacology findings, not controlled demonstrations of subjective effects or toxicity in humans.
Toxicon · Gymnopilins and nicotinic acetylcholine receptors
Controlled human trials — purified psilocybin (comparison only)
Goodwin et al. (2022) — phase-2 treatment-resistant depression trial
233 participants received varying controlled amounts of investigational purified psilocybin with clinical support. The study reported short-term changes in depressive symptom scores and adverse events that included headache, nausea, dizziness, suicidal ideation or behavior, and self-injury in study groups. It is not evidence that this wild specimen treats depression.
New England Journal of Medicine · DOI 10.1056/NEJMoa2206443
Carhart-Harris et al. (2021) — psilocybin versus escitalopram trial
A controlled comparison of purified psilocybin and escitalopram reported psychological outcomes and treatment-emergent effects; headache was frequently recorded. Results concern supervised pharmaceutical research, not foraged fungi.
New England Journal of Medicine · DOI 10.1056/NEJMoa2032994
Community experience archive — self-selected, unverified reports
These links are preserved as firsthand narrative material. Dates and identities are reported by posters, not authenticated. Accounts involving other substances are confounded. Numerical potency comparisons and consumption instructions from the threads are intentionally not adopted into the atlas.
Reddit · Laughing Gym Question (2024 thread with 2025–2026 replies)
One contributor recalled an enjoyable altered experience from historical mail-order material, followed by a separate occasion with little or no effect. Another described relaxation and unusual bodily sensations. Neither post contains independent compound assays or confirmed taxonomic vouchers.
Read the source discussion
Reddit · Anyone tried Laughing Jims? (September 2026)
The conversation includes a firsthand claim of laughing and mild subjective effects, plus concerns about nausea and uncertain identification. Other replies are speculation or discussion of different species; do not count them as verified observations of G. junonius.
Read the source discussion
Erowid · Self-described G. spectabilis experience (2001)
A poster described mood alteration and slight visual effects. Self-identification was reported but not laboratory-confirmed; alcohol and cannabis were also mentioned, preventing attribution to the mushroom alone.
Read the experience narrative
Erowid · Multiple-substance narrative (2000)
An author described an altered psychedelic experience after combining material identified as G. spectabilis with Syrian rue and cannabis. The combination makes attribution to Gymnopilus alone impossible. The co-ingestions may have clinically significant interactions.
Read the confounded account
Research classification: human dose not established; specimen activity not verified; clinical therapeutic claims not established for Gymnopilus; chemical composition requires authenticated specimen and analytical testing. Online testimony is not clinical evidence.
Measured specimen morphology — 17 October 2026
Observer-reported measurements in centimeters. The measurements are not individually matched to specific photographs or developmental ages.
Cap diameters: 13.5 · 19.5 · 12 · 11 · 7.5 cm. Additional measurement: The additional 6–7 cm cap observation was confirmed in centimeters by the observer; it remains unclear whether this represents two caps or one approximate range.
Margin: approximately 1 cm thick; sometimes wavy or undulating.
| Stem profile | Top | Middle / lower stem | Bulbous base |
| A — robust | 1.5 cm | 1.7–1.8 cm | 3 cm |
| B — slender | 1 cm | 1 cm lower stem | 1.5 cm |
| C — thick | 2 cm | 2.1 cm | 2.5 cm |
Measured heights: 3 · 5 · 5.5 · 7.8 · 10.2 · 11.5 cm; observed range 3–11.5 cm. Stipes are approximately equal in width along their length, widening near the base.
3D calibration note: use these measurements to guide proportional modeling; do not imply that an unmeasured age model has a confirmed size. Morphology does not independently establish species identity.
Export detailed morphometrics JSON
Gym Juno — Classified spore microscopy (11 original images)
Accession: GYM-JUNO-MICRO-2026-10-18 · 11 user-supplied microscope screenshots, indexed GJ-MIC-01 through GJ-MIC-11. This dossier is restricted to the existing classified research page; its scientific identity remains provisional pending microscopy review and voucher confirmation.
Observed morphology: multiple ellipsoid, curved, and crescent-like refractile structures, some overlapping. Not every visible shape can be confidently classified as an isolated basidiospore from photographs alone. Shape distortions, orientation, non-spore structures, and mounting artifacts are alternative explanations.
Measurement annotations: screenshot 2 displays seven on-screen length labels: 9.06, 3.64, 10.77, 4.43, 5.75, 4.00, and 4.50 µm. These refer to individual software line segments and cannot be assumed to represent validated spore lengths, widths, or a species-level size distribution. Other images show additional annotated values requiring a structured calibration audit.
Microscopy protocol HOLD: determine objective magnification, calibration method, mounting medium, and sampling approach. Record paired length × width of non-overlapping verified spores, with a separate ornamentation assessment. Taxonomic assignment, toxicity and compound-content claims must not be inferred from these pictures alone.
Viewing original images: import the 11 PNG images (or one original-image ZIP, including standard compressed ZIPs) in the photograph archive directly below. Choose Microscopy / spore studies in Study group to show only these images. Originals remain on this browser and are not published to the public static repository.
Download classified microscopy specimen register (JSON)
Security limitation: this static page uses a client-side passcode, not server-side authentication. The images are intentionally not hosted as unencrypted public assets.
Gym Juno — AES-256-GCM encrypted specimen originals
This gallery is designed for 71 authentic original photographs encrypted with a randomly generated 256-bit key. The confidential recovery key is separate from the historical specimen passcode, is not sent to GitHub or Render, and is not stored by the Atlas. The public repository may carry only ciphertext, encrypted-file hashes and nonsecret grouping metadata.
Checking encrypted asset deployment...
Security limits: anyone who obtains the recovery key can decrypt the photographs. The page passcode is only a convenience gate and is not server authorization. Gallery release stays on HOLD until all 71 encrypted binaries and manifest are verified on the production deployment.
Private multi-computer Gym Juno photograph archive
Independent authentication is required. Unlike the specimen's client-side access screen, the image bucket enforces ownership rules before sending any photograph. Cloud setup is disabled until a free storage project is configured. This gallery never serves originals from public GitHub paths.
Checking protected storage configuration...
Owner authentication and private object-storage policies protect access; no claim of classified-system certification. Do not upload until the designated research account has been created and access rules reviewed.
Gym Juno — Classified original photograph gallery (71 images)
71 original photographs recorded: 60 field/anatomy photographs (IMG_1576–1635) and 11 microscopy PNGs. Important: the photos are NOT automatically uploaded from ChatGPT to the live static site. To view the originals here without publishing them to the public repository, download the combined 71-photo ZIP supplied in the chat and import it once in this browser. It stays on this device only.
Gallery initializing. If no photographs appear, import the 71-photo ZIP from our chat into this browser; no images are stored on the website.
Private-gallery note: IndexedDB keeps photos on this browser/device only. Other computers require their own import. This browser storage is not an encrypted research vault; avoid sharing this browser profile.
Interactive molecular and receptor pathway simulator
Study the conditional psilocybin–psilocin–5-HT2A cascade separately from the experimentally observed gymnopilin–nicotinic acetylcholine receptor response. These two mechanisms must not be conflated.
3D molecular signaling laboratory Schematic educational visualization
Conditional serotonergic signaling
Requires verified compound presence in specimen.
Drag to orbit; scroll to zoom. Molecular components are symbolic, not atomic-resolution structures.
Stage 1
Quantitative integrity: A 2014 PC12-cell assay reported approximately 50% suppression of an acetylcholine-evoked calcium signal. That is neither a mushroom compound percentage nor a human adverse-event rate. The occurrence and concentration of psilocybin or psilocin in these photographed mushrooms remain unverified.
Taxonomy: Gymnopilus spectabilis historically applied within the G. junonius complex. Attribution to a modern taxon requires morphology plus voucher and, preferably, molecular analysis. This is a research reconstruction, never an identification authority.
Research evidence ledger — primary studies
- Hatfield, Valdes & Smith (1978), Lloydia 41:140–144. PMID 565861. Psilocybin detected in screened G. spectabilis material. Assay detection capability: 0.0004% dry weight; NOT measured species concentration. The cited 0.12% isolation yield belongs to G. validipes, NOT G. spectabilis.
- Kusano, Koike, Inoue & Nozoe (1986), Chemical & Pharmaceutical Bulletin 34:3465–3470. DOI. Did NOT detect psilocybin-related compounds in their collections; reported cerevisterol, an acetylenic triol, ergosterol, ergosteryl peroxide and choline.
- Kayano et al. (2014), Toxicon 81:23–31. DOI. Gymnopilins isolated from Japanese G. junonius inhibited nicotinic acetylcholine receptor signaling in PC12 cells; acetylcholine-evoked intracellular Ca²⁺ response fell by approximately 50% under tested conditions. They also inhibited nicotine/DMPP responses, without suppressing tested voltage-gated Ca²⁺ channel currents.
Mechanism A — serotonergic (conditional on analytical psilocybin confirmation)
Psilocybin → phosphatases → psilocin → 5-HT2A receptor → Gq/11 → phospholipase C-β → IP3 + DAG → intracellular calcium release and protein kinase C signaling → altered cortical network activity. This is a general psilocin mechanism, not evidence that any specific collected mushroom contains psilocybin.
Mechanism B — gymnopilin pharmacology (cultured-cell evidence)
Gymnopilin-containing fraction → nicotinic acetylcholine receptor inhibition → diminished agonist-evoked membrane currents / downstream calcium responses. Exact human dose-response, absorption and clinical effect size are unestablished. Do not conflate nAChR inhibition with 5-HT2A agonism.
Constituents and numerical evidence
Psilocybin: reported in some identified samples, absent in others; reliable universal dry-weight percentage: not established. Psilocin: specimen-specific percentage not established. Gymnopilin percentage by mass: not established. Approximately 50%: a cultured-cell assay response reduction, NOT mushroom composition or human incidence. Historical 0.0004%: method detection threshold, NOT concentration. Ergosterol, ergosteryl peroxide, cerevisterol, choline and an acetylenic triol: isolated by Kusano et al. in the examined collection.
GYMNOPILIN NEUROPHARMACOLOGY · Evidence and Mechanisms
Scientific status: in-vitro and limited animal-tissue evidence. No confirmed human mechanism of hallucination; no validated human onset, duration, pharmacokinetics, or percentage composition for these specimen photographs.
1. Identity, chemical class and specimen scope
Gymnopilins are bitter polyisoprenoid polyols (polyisoprene-derived molecules bearing hydroxyl groups). Historically related gymnoprenol compounds were isolated from material called G. spectabilis. The names G. spectabilis and G. junonius appear in overlapping older literature; isolate identity must be tied to collection/voucher and analytical method. Individual compounds have variable structures and activities. Chemical presence cannot be established from visual appearance.
Interpretation: gymnopilins are experimentally neuroactive and possible contributors to poisoning, but evidence does not prove they independently generate psychedelic hallucinations.
2. Cellular pathway I — nicotinic acetylcholine receptor (PC12, 2014)
Gymnopilin fractions → nicotinic acetylcholine receptor (nAChR, ligand-gated cation channel) inhibition → decreased DMPP-evoked whole-cell current and reduced nicotinic agonist-evoked intracellular Ca²⁺ rises. In the specific acetylcholine assay, calcium-response amplitude decreased by approximately 50%. Voltage-gated Ca²⁺ channel currents were not reduced under the reported conditions.
Level: cultured PC12 cells. ~50% is an assay effect size, not fungal mass fraction, human incidence, or predicted human response. Kayano et al. (2014), PubMed; DOI.
3. Cellular pathway II — PLC / intracellular calcium (DRG cultures, 2012)
Purified gymnopilin → increased intracellular Ca²⁺ concentrations in rat dorsal-root-ganglion cultures, including neuronal and non-neuronal cells. In the non-neuronal population, U-73122 (PLC inhibitor) and cyclopiazonic acid (intracellular store Ca²⁺-ATPase inhibitor) suppressed the gymnopilin-evoked response, while extracellular calcium removal did not. Results implicate phospholipase C and calcium release from intracellular stores; the precise initiating receptor was not identified.
Level: isolated rat cell cultures, not a human brain study. Miyazaki et al. (2012), PubMed PMID 22572385.
4. Other isolated constituents — do not assume hallucinogenic activity
| Compound | Observed chemical or biological role | Human hallucination evidence |
| Gymnopilins / gymnoprenol-related polyols | Neurophysiological effects in cell systems; bitterness | Unconfirmed causal role |
| Hispidin | Isolated from 2008 Korean material; radical-scavenging activity in chemical assays | Not established |
| Bisnoryangonin | Styrylpyrone isolated in 2008; antioxidant chemical assays | Not established |
| Ergosterol and derivatives | Sterol constituents characterized in some collections | Not established |
| 4,6-Decadiyne-1,3,8-triol | Isolated acetylenic metabolite; no radical scavenging up to tested assay limits in 2008 | Not established |
Lee et al. (2008), Mycobiology 36:55–59, DOI 10.4489/MYCO.2008.36.1.055. This paper isolated 4,6-decadiyne-1,3,8-triol, ergosta-4,6,8(14),22-tetraen-3-one, bisnoryangonin and hispidin; it did not directly establish psilocybin quantities or human psychotropic potency.
5. Hallucinations: causal uncertainty and comparison with psilocin
Gymnopilin → nAChR inhibition: cell evidence. Gymnopilin → PLC-associated intracellular Ca²⁺ rise: rat-culture evidence. Gymnopilin → human hallucinations: unverified causal hypothesis. Psilocybin → psilocin → 5-HT2A receptor: established general pharmacology but relevant to a particular specimen only when compound content has been measured.
Do not draw a mechanistic arrow from nicotinic inhibition directly to human hallucinations as established fact. Compounds could interact, collection chemistry can differ and taxonomic misidentification complicates the older literature.
6. Quantitative limitations, safety and simulator requirements
Gymnopilin % dry weight: unestablished here. Verified universal psilocybin % for this taxon: unestablished. Human gymnopilin onset/peak/half-life/duration: unestablished. Human hallucination frequency and individual intoxication risk: unestablished. The 2014 ~50% endpoint belongs only to the experimental PC12 calcium-response assay.
Simulator policy: separately display measured chemistry, cellular mechanism, hypothesized human relevance, and unknowns. No ingestion or identification guidance should be inferred from a 3D shape.
Access note: this research section is visually hidden until the specimen unlocks, but static HTML source is still readable by anyone who can access the page. For genuinely confidential research, server-enforced access controls or encryption of the research text are required.
Photograph-to-3D scientific reconstruction protocol
Upcoming imagery will be reviewed before mesh changes; images themselves are not yet attached. Preserve unmodified originals and specimen provenance. Each specimen photo group should contain dorsal cap view, ventral gills, lateral stipe and annulus, cluster in situ, hardwood substrate, ruler/scale and mature/immature stages when available. Record date, substrate tree, locality at a privacy-appropriate level, scale in mm, field versus laboratory image, focal length if known, specimen/voucher ID and any uncertainty.
Reconstruction pipeline: source photo → specimen photo ID → scale calibration → segmented geometry (pileus, lamellae, stipe, annulus, substrate) → texture and shape adjustments → multi-angle visual validation → retained prior model version. A photo cannot independently establish metabolite presence or safe identification.
Safety: Possible poisoning and misidentification. This model is an educational visualization; it does not support ingestion decisions or identification of wild mushrooms.
Open companion Google Drive research record